In Rakai, Uganda, human immunodeficiency virus (HIV)-positive men were randomized to undergo either immediate circumcision (intervention arm) or delayed circumcision (control arm). Penile swab samples were assayed for high-risk human papillomavirus (HR-HPV) by Roche HPV Linear Array at enrollment and at 24 months (intervention arm, 103 subjects; control arm, 107 subjects). Rate ratios (RRs) of HR-HPV were estimated by Poisson regression. At 24 months, HR-HPV prevalence was found in 57 (55.3%) of 103 subjects in the intervention arm and in 77 (71.7%) of 107 subjects in the control arm (RR, 0.77; 95% confidence interval [CI], 0.62-0.97). Multiple HR-HPV infections were found in 19 (22.4%) of 85 subjects in the intervention arm and in 45 (42.5%) of 106 subjects in the control arm (RR, 0.53; 95% CI, 0.33-0.83). New HR-HPV genotypes were acquired by 34 (42.0%) of 81 subjects in the intervention arm and by 53 (57.0%) 85 subjects in the control arm (RR, 0.74; 95% CI, 0.54-1.01;
human immunodeficiency virus (HIV) acquisition in men by 50%-60% [1] [2] [3] , and the World Health Organization (WHO) now recommends that circumcision be provided as a component of HIV prevention programs [4] . It is inevitable that as male circumcision services become widely available, HIV-infected men will request the procedure, and WHO recommends that they should be provided with circumcision unless there are medical contraindications for surgery [4] . We previously reported that surgery-related complications were comparable in HIV-infected and HIV-uninfected men [5] , and that circumcised HIV-positive men had reduced rates of genital ulcer disease [6] .
Two trials of male circumcision have shown a reduced prevalence of penile high-risk human papillomavirus (HR-HPV) infection in circumcised HIV-neg-ative men [7, 8] . However, the effects of circumcision on HR-HPV infection in men with HIV are unknown. HIV infection is associated with high rates of HR-HPV infection and cervical neoplasia in women [9, 10] and with HR-HPV infection and penile and anal cancers in men [11] [12] [13] [14] . Therefore, if circumcision reduces penile carriage of HR-HPV in HIV-positive men, it may provide a health benefit to these men and potentially to their female sex partners. In this article, we report on the efficacy of circumcision for prevention of penile HR-HPV infections in a randomized trial of HIV-infected men in Uganda.
METHODS
We conducted 2 parallel trials of male circumcision in HIVnegative and HIV-positive men in the Rakai district of southwestern Uganda from 2003 to 2007. The design and conduct of the trials has been described elsewhere [3, 15] . In brief, both HIV-infected and HIV-uninfected men were informed of the trial objectives and procedures, and consenting men were then screened for eligibility. Criteria for enrollment included being uncircumcised, being 15-49 years of age, and having no indications for or contraindication to surgery. Men found to have genital infections or a hemoglobin level р8 g/dL were treated and rescreened. All screened participants were offered voluntary HIV counseling and testing, health education on HIV and sexually transmitted infection prevention, and free condoms.
HIV status at enrollment was assessed by 2 enzyme immunoassays: Vironostika HIV-1 (Organon Teknika) and Recombigen (Cambridge Biotech). Discordant enzyme immunoassay results were confirmed by Western blot analysis (Calypte Biomedical).
Because the safety of surgery in HIV-infected men was unknown, we excluded HIV-positive men from enrollment if they had evidence of immunosuppression, as indicated by a CD4 cell count !350 cells/mL or WHO clinical stage 3 or stage 4 disease. All HIV-infected men were referred for management of their HIV disease by the Rakai Health Sciences Program's HIV care services, supported by the President's Emergency Fund for AIDS Relief. All HIV-infected men received a basic care package of trimethoprim-sulfamethoxazole prophylaxis, insecticide-saturated bed nets, and hypochlorite water disinfection packets. Men with a CD4 cell count !250 cells/mL or WHO stage 4 disease were advised to initiate antiretroviral therapy, which was available free of charge through the Rakai Program.
Eligible participants provided written informed consent for enrollment, which described study procedures, potential risks and benefits, and the voluntary nature of participation. Men who were randomized to the intervention arm underwent circumcision within 2 weeks of enrollment using the sleeve procedure under local anesthesia and were followed up postoperatively at 1-2 and 7-9 days and 4-6 weeks. All participants in the intervention and control arms were followed up at 6, 12, and 24 months. At enrollment and at each follow-up visit, participants completed an interview to ascertain sociodemographic characteristics, sexual risk behaviors, and symptoms suggestive of sexually transmitted infections or AIDS.
At each visit, clinical officers examined the men's genitalia, recorded any abnormalities, and took a penile swab sample for HPV detection. Moistened Dacron swab samples were obtained from the subpreputial cavity of uncircumcised men and from the coronal sulcus/glans of circumcised men, placed in Digene specimen transport medium, and stored at Ϫ80ЊC until assay. HPV genotyping was performed using the Roche HPV Linear Array (Roche Diagnostics), as described elsewhere [16] [17] [18] Penile swab test results that were negative for both HPV and the b-globin internal control were considered to be insufficient for HR-HPV detection and were excluded from HPV analyses [19, 20] .
The trial profile is shown in Figure 1 . There were 1151 HIVinfected men identified at screening, of whom 922 (80.1%) were enrolled and randomized to either the intervention arm ( ) or the control arm ( ). The lack of balance n p 474 n p 448 between the study arms was due to the fact that enrollment and randomization were decentralized in these rural communities and took place at 10 sites. Also, all men (HIV-infected and HIV-uninfected) were randomized at the time of enrollment. Thus, imbalances due to chance occurred in the number of subjects allocated to the intervention and control arms. Because of financial constraints and assay costs, we only tested a random sample of HIV-positive participants who provided penile swab samples at enrollment and at the 24-month follow-up. Resources were insufficient to assay samples at the 6-and 12-month visits. There were 103 enrollment samples tested in the intervention arm (21.7% of men enrolled) and 107 in the control arm (23.9% of men enrolled). At the 24-month follow-up, assay results were available for 93 men in the intervention arm (90.3% of those tested at enrollment). Ten samples from the intervention arm were excluded because of insufficient volume or suspected contamination. There were 8 cross-overs in the intervention arm, defined as men who did not accept circumcision by 6 months after randomization. Follow-up assays were conducted for all 107 men in the control arm, and there were no control cross-overs.
The trials were approved by 2 institutional review boards in Statistical analysis. Characteristics, behaviors, and HR-HPV infections were assessed by arm of assignment at enrollment. We assessed the efficacy of circumcision for reduction of prevalent HR-HPV by using an intention-to-treat analysis, based on 2 classifications of HR-HPV outcomes: (1) the prevalence of any (у1 HR-HPV infections) and (2) the prevalence of single or multiple (у1) HR-HPV infections at the 24-month follow-up. Similar analyses were conducted for LR-HPV infections. An as-treated analysis classified intervention arm cross-overs as uncircumcised if they did not accept surgery by the 6-month visit. There were no control arm cross-overs in this analytic sample. The units of observation were individual study participants. The prevalence risk ratio (PRR) of HR-HPV in the intervention arm relative to the control arm was estimated by comparing the 2 binomial proportions.
The incidence of new HR-HPV infections at 24 months was determined among men who were either HR-HPV negative at enrollment or who were HR-HPV positive for a given genotype but who had acquired a new HR-HPV genotype at follow-up. The denominator for estimate of incidence consisted of men with valid samples at both enrollment and at the 24-month follow-up. Incidence was estimated as the proportion of men with a new HR-HPV infection at the 24-month follow-up. We assessed acquisition of any (ie, у1) new HR-HPV infection, as well as single and multiple infections per person. The proportion of new genotype-specific infections was estimated from the number of new genotypes detected at the 24-month followup among men with samples that tested negative for the newly acquired genotypes at enrollment. The incidence rate ratio (IRR) of new HR-HPV infections acquired over 24 months was estimated by Poisson log linear regression. Adjusted IRRs were estimated by multivariable Poisson regression and included covariates for age, marital status, number of sex partners, condom use, and alcohol consumption with sex.
The clearance of preexisting genotype-specific HR-HPV infections over 24 months was estimated from the proportions of prevalent genotype-specific infections detected at enrollment that were not detected at follow-up, among samples with amplifiable viral or cellular DNA at both time points. The clearance ratio of any HR-HPV genotype infection was estimated using a log binomial model with robust variance estimates, assuming 
RESULTS
At enrollment, the 2 study arms were comparable with respect to age, education, condom use, numbers of sex partners, and alcohol consumption with sex within the prior year ( Table 1) . The percentage of currently married men in the intervention arm (23.5%) was lower than that in the control arm (33.6%), but this difference was not statistically significant ( ). P p .11 A high proportion of these HIV-positive men had HR-HPV infections at enrollment (Table 2 ), but the percentages with HR-HPV infections were comparable between the intervention arm (72.2%) and the control arm (76.6%). The percentage of men infected with у2 HR-HPV genotypes at enrollment was 49.5% in the intervention arm and 47.9% in the control arm. At the 24-month follow-up, the percentage of HIV-positive men with у1 HR-HPV genotypes was 55.3% in the intervention arm and 71.7% in the control arm (PRR, 0.77; 95% CI, 0.62-0.97). The percentage of men with у1 HR-HPV among the intervention arm decreased from enrollment to follow-up (72.2% and 55.3%, respectively; ), whereas there was P p .02 no change over time in the percentage of men in the control arm infected with у1 HR-HPV genotypes (76.6% at enrollment and 71.7% at follow-up, respectively;
). The prevalence P p .52 of single HR-HPV genotype infections did not differ significantly between study arms at the 24-month follow-up (PRR, 1.13; 95% CI, 0.74-1.72). However, the prevalence of multiple (ie, у2) HR-HPV genotype infections at the 24-month followup was markedly lower in the intervention arm (22.4%) than in the control arm (42.5%; PRR, 0.53; 95% CI 0.33-0.83).
The frequency of new HR-HPV infections is shown in Table  3 . In an intention-to-treat analysis, the percentage of men acquiring any (ie, у1) new HR-HPV genotype infection was lower in the intervention (42.0%) than in the control arm (57.0%), and this was of borderline statistical significance (IRR, 0.74; 95% CI, 0.57-1.01). After multivariate adjustment for marital status and number of sex partners, the adjusted IRR was 0.68 (95% CI, 0.44-1.04). There was no effect of circumcision on the proportions acquiring a single new HR-HPV genotype infection (IRR, 1.00; 95% CI, 0.65-1.53). However, the percentage of men who acquired multiple new HR-HPV Table 4 shows the proportion of men who acquired a new HR-HPV genotypic infection among men whose test results were negative for each specific genotype at enrollment. The acquisition of new HR-HPV genotypes was lower in the intervention arm than in the control arm for 13 of the 14 HR-HPV genotypes, but none of these differences between study arms were statistically significant.
At enrollment, the prevalence of low-risk HPV (LR-HPV) genotypes was 83 (85.6%) of 97 in the intervention arm and 78 (83.0%) of 94 in the control arm (PRR, 1.03; 95% CI, 0.91-1.17). At the 24-month follow-up, the prevalence of LR-HPV genotypes decreased to 42 (49.4%) of 85 men in the intervention arm but remained relatively stable at 82 (77.4%) of 106 men in the control arm, and the prevalence rate ratio was significantly reduced (PRR, 0.64; 95% CI, 0.50-0.81). Table 5 shows the genotype-specific HPV clearance rates by study arm. In the intervention arm, a total of 147 HR-HPV genotype infections were detected at enrollment, and 112 (76.2%) of these infections had cleared by 24 months. In the control arm, there were a total of 182 HR-HPV genotype infections detected at enrollment, of which 131 (71.0%) infections had cleared at NOTE. The denominators are samples that had amplifiable cellular or viral DNA at both enrollment and follow-up, and were negative for the specific genotype at enrollment. CI, confidence interval; RR, rate ratio. follow-up. This difference was not statistically significant (RR, 1.09; 95% CI, 0.94-1.27), after adjusting for correlation between clearance events observed within the same individual.
DISCUSSION
Circumcision of HIV-infected men with CD4 cell counts 1350 cells/mL and no evidence of AIDS-related illnesses reduced the prevalence and incidence of infection with multiple HR-HPV and LR-HPV genotypes over 24 months but did not affect acquisition of single HR-HPV genotype infections or clearance of preexisting HR-HPV infections.
We are not aware of other studies that have assessed the effects of male circumcision in HIV-infected men, so our findings need to be replicated. Nevertheless, these observations in HIV-positive men are compatible with the protective effects of circumcision observed in trials of HIV-negative men, among whom circumcision was found to have an efficacy of 35%-36% for prevention of prevalent HR-HPV infection [7, 8] , compared with the 23% efficacy observed in HIV-positive men (Table 2) . Also, circumcision was found to have a more marked effect on the prevalence of multiple HR-HPV infections in both HIV-negative men (65% efficacy) [8] and HIV-positive men (47% efficacy) ( Table 2) . Similarly, with respect to HR-HPV incidence, the efficacy for prevention of any (ie, у1) HR-HPV genotype infection was 33% for both HIV-negative and HIVpositive men (Table 3 ). The efficacy for prevention of multiple HR-HPV genotypes was also comparable in HIV-uninfected men (35%) and HIV-infected men (37%, Table 3 ). It is noteworthy that circumcision did not affect the incidence of single HR-HPV infections in either HIV-negative or HIV-positive men (Table 3) . Additionally, circumcision reduced the prevalence of LR-HPV infections in both HIV-infected and HIVuninfected men. Thus, circumcision appears to have comparable efficacy for the prevention of HR-HPV infections irrespective of HIV coinfection.
Our findings suggest that male circumcision may provide a direct benefit for HIV-positive men by preventing penile HR-HPV infection and thus potentially averting penile cancer. In addition, couples studies show that HIV/HPV coinfection is strongly associated with increased HPV infection in sex partners [13] , so it is possible that circumcision of HIV-infected men may protect female partners from infection and potentially from cervical neoplasia [12] .
There are limitations to this study. Because of resource constraints, the number of samples assayed was small and this limited study power. The 24-month interval between repeat HPV testing was long, and it is likely that we missed incident HR-HPV infections that cleared before the 24-month followup visit. Because we observed no difference in HR-HPV clearance between study arms in the HIV-infected men, any failure to detect incident HR-HPV infections that cleared before the 24 month follow-up visit is likely to be nondifferential between study arms and thus should not bias estimates of efficacy. As noted above, the efficacy of circumcision for prevention of any HR-HPV infection was similar in HIV-positive men (65%) and HIV-negative men (63%), suggesting that any underascertainment did not introduce serious bias. The protracted follow-up interval did not allow precise estimation of clearance (and thus duration of infection) in these HIV-infected men, and we observed no effect of circumcision on HR-HPV clearance (Table  5) . Nevertheless, the rates of clearance over 24 months in the present study are similar to those observed in the trial of HIVnegative men, although in that study, we did observe significantly increased clearance rates in the intervention arm ( ). P p .004 An additional limitation is that the HR-HPV assays were performed on swab samples obtained from the coronal sulcus/ glans, and some studies of multiple anatomical sampling sites suggest lower detection of HPV from this area, compared with the shaft [19, 20] . However, other studies found somewhat higher rates of HPV detection from samples taken from the coronal sulcus/glans than from the shaft [21] . Therefore, it is unlikely that the sampling site used here led to serious underascertainment of infection. We have no explanation for the finding that circumcision reduced the incidence of multiple HR-HPV genotypes but had no effect on acquisition of singlegenotype infections. Additional studies are needed to confirm that circumcision results in an overall lower burden of genital tract HR-HPV in HIV-infected men. We cannot assess whether the observed effects of circumcision on reducing multiple HR-HPV genotype infections has implications for the development of penile or cervical neoplasia. Nor can we determine whether circumcision of men with CD4 cell counts !350 cells/mL or with AIDS-defining illnesses will affect HR-HPV carriage.
Finally, we were not able to determine whether the effect of circumcision on reducing the incidence of HR-HPV reflects protection against acquisition of new HR-HPV genotypes or protection against reactivation of a latent infections. Whatever the mechanism, the marginal reduction in HPV detectability is likely to reflect a decrease in viral shedding (at least from the coronal sulcus/glans), which may be expected to decrease transmission risk to female partners.
In summary, we conclude that circumcision of HIV-infected men significantly reduced the incidence and prevalence of multiple HR-HPV and LR-HPV infections and thus provides a direct health benefit to these individuals and potentially a benefit to their sex partners.
